Diagnosis and management of thyrotoxicosis

American Family Physician

Volumn 54, Issue 4, 1996, Pages 1315-1324

  Hennessey, James V ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE PLUS PERPHENAZINE; ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; CHORIONIC GONADOTROPIN; CLOFIBRATE; DEXAMETHASONE; DIAMORPHINE; IODINE 131; LEVOTHYROXINE; LIOTHYRONINE; LITHIUM; METHADONE; ORAL CONTRACEPTIVE AGENT; PERPHENAZINE; PROPYLTHIOURACIL; THIAMAZOLE; THYROXINE;

ARTHRALGIA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; GRANULOCYTOSIS; HUMAN; HYPERTHYROXINEMIA; HYPOTHYROIDISM; PRURITUS; RADIOISOTOPE THERAPY; RASH; REVIEW; THYROID CRISIS; THYROIDECTOMY; TOXIC HEPATITIS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; THYROTOXICOSIS;

EID: 0029790838     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Braverman LE, Utiger RD. Introduction to thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's the thyroid: a fundamental and clinical text. 6th ed. Philadelphia: Lippincott, 1991:645-7.
2. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol 1995;43:55-68.
3. Garcia M, Baskin HJ, Feld S, Cobin RH, Davidson ET, Dickey RA, et al. AACE treatment guidelines for hyperthyroidism and hypothyroidism. Endocr Practice 1995;1:54-62.
4. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 1995;273:808-12.
5. Nordyke RA, Gilbert FI Jr, Harada AS. Graves' disease. Influence of age on clinical findings. Arch Intern Med 1988;148:626-31.
6. Houston MS, Hay ID. Practical management of hyperthyroidism. Am Fam Physician 1990;41:909-16.
7. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993;365:649-51.
8. Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994;330:1731-8 [Published erratum appears in N Engl J Med 1994;331:559].
9. Fradkin JE, Wolff J. Iodide-induced thyrotoxicosis. Medicine 1983;62:1-20.
10. Hedberg CW, Fishbein DB, Janssen RS, Meyers B, McMillen JM, MacDonald KL, et al. An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N Engl J Med 1987;316:993-8.
11. Kinney JS, Hurwitz ES, Fishbein DB, Woolf PD, Pinsky PF, Lawrence DN, et al. Community outbreak of thyrotoxicosis: epidemiology, immunogenetic characteristics, and long-term outcome. Am J Med 1988;84:10-8.
12. Stockigt JR. Serum thyrotropin and thyroid hormone measurements and assessment of thyroid hormone transport. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's the thyroid: a fundamental and clinical text. 6th ed. Philadelphia: Lippincott, 1991:463-92.
13. Kahn BB, Weintraub BD, Csako G, Zweig MH. Factitious elevation of thyrotropin in a new ultrasensitive assay: implications for the use of monoclonal antibodies in "sandwich" immunoassay. J Clin Endocrinol Metab 1988;66:526-33.
14. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991;1:129-35.
15. Hennessey JV, Berg LA, Ibrahim MA, Markert RJ. Evaluation of early (5 to 6 hours) iodine 123 uptake for diagnosis and treatment planning in Graves' disease. Arch Intern Med 1995;155:621-4.
16. Burrow GN. Thyroid function and hyperfunction during gestation. Endocr Rev 1993;14:194-202.
17. Wartofsky L. Guidelines for the treatment of hyperthyroidism. Am Fam Physician 1984;30:199-210.
18. Cooper DS. Antithyroid drugs. N Engl J Med 1984;311:1353-62.
19. Sobel R, Glick S. Monitoring antithyroid therapy [Letter]. Arch Intern Med 1993;153:2797.
20. Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 1990;150:621-4.
21. Duncan WE, Chang A, Solomon B, Wartofsky L. Influence of clinical characteristics and parameters associated with thyroid hormone therapy on the bone mineral density of women treated with thyroid hormone. Thyroid 1994;4:183-90.
22. Rosen CJ, Adler RA. Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab 1992;75:1531-4.
23. Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, et al. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991;324:947-53.
24. Weetman AP. The immunomodulatory effects of antithyroid drugs [Editorial]. Thyroid 1994;4:145-6.
25. Taurog A. Hormone synthesis: thyroid iodine metabolism. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's the thyroid: a fundamental and clinical text. 6th ed. Philadelphia: Lippincott, 1991:51-97.
26. Totterman TH, Karlsson FA, Bengtsson M, Mendel-Hartvig I. Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease. N Engl J Med 1987;316:15-22.
27. Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. J Clin Endocrinol Metab 1993;76:1516-21.
28. Roti E, Gardini E, Minelli R, Salvi M, Robuschi G, Braverman LE. Methimazole and serum thyroid hormone concentrations in hyperthyroid patients: effects of single and multiple daily doses. Ann Intern Med 1989;111:181-2.
29. Shiroozu A, Okamura K, Ikenoue H, Satok K, Nakashima T, Yoshinari M, et al. Treatment of hyperthyroidism with a small single daily dose of methimazole. J Clin Endocrinol Metab 1986;63:125-8.
30. Romaldini JH, Bromberg N, Werner RS, Tanaka LM, Rodrigues HF, Werner MC, et al. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983; 57:563-70.
31. Tamai H, Hayaki I, Kawai K, Komaki G, Matsubayashi S, Kuma K, et al. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients. J Clin Endocrinol Metab 1995;80:1481-4.
32. McIver B, Rae P, Beckett G, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996;334:220-4.
33. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 1992;326:1733-8.
34. Wenzel KW. Thyroid hormone and bone [Letter]. Thyroid 1994;4:508-9.
35. Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen. JAMA 1994; 271:1245-9.
36. Klein I, Trzepacz PT, Roberts M, Levey GS. Symptom rating scale for assessing hyperthyroidism. Arch Intern Med 1988;148:387-90.
37. Klein I, Becker DV, Levey GS. Treatment of hyperthyroid disease. Ann Intern Med 1994;121:281-8.